GC
ONCT

Guggenheim Capital’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Guggenheim Capital’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-17
Closed -$19K – 2999
2016
Q3 		$19K Buy
+17
New +$14.8K ﹤0.01% 2829
2014
Q2 		– Sell
-14
Closed -$30K – 3318
2014
Q1 		$30K Buy
14
+2
+17% +$4.98K ﹤0.01% 3197
2013
Q4 		$29K Buy
12
+5
+71% +$11.4K ﹤0.01% 3104
2013
Q3 		$21K Buy
+7
New +$34.8K ﹤0.01% 3012

Other funds holding ONCT

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FHA
First Horizon Advisors Memphis, Tennessee $3.85B AUM 16.99% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
DAM
Delta Asset Management Memphis, Tennessee $1.1B AUM 14.89% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
KLI
Kelman-Lazarov Inc Memphis, Tennessee $698M AUM 14.07% 1-Year Est. Return

Guggenheim Capital's ONCT Position: Q4 2016 in Review

Guggenheim Capital sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q4 2016, closing a stake of 17 shares — an estimated $19K sold.

Guggenheim Capital first reported a position in ONCT in Q3 2013 and held it in 4 quarters. The position peaked at $30K in Q1 2014. 21 funds tracked by Wall St. Rank hold ONCT as of Q4 2016.

  • Guggenheim Capital reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q4 2016 after selling out during the quarter.
  • Guggenheim Capital sold 17 Oncternal Therapeutics, Inc. Common Stock shares in Q4 2016, an estimated $19K.
  • Guggenheim Capital first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q3 2013 and held it in 4 quarters.
  • Guggenheim Capital's Oncternal Therapeutics, Inc. Common Stock position peaked at $30K in Q1 2014.
  • 21 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q4 2016.

Based on Guggenheim Capital's 13F filing for Q4 2016, filed 14 Feb 2017.